Navigation Links
ChromaDex Announces Second Quarter 2008 Financial Results
Date:8/12/2008

IRVINE, Calif., Aug. 12 /PRNewswire-FirstCall/ -- ChromaDex Corporation, (OTC Bulletin Board: CDXC) a leader in phytochemical reference standards and contract research, today announced financial results for the second quarter of 2008. On a reported basis calculated in accordance with U.S. Generally Accepted Accounting Principles (GAAP), ChromaDex announced a net loss attributable to common stockholders of $0.03 per share for the three months ended June 28, 2008.

As of June 28, 2008, cash, cash equivalents, and marketable securities totaled approximately $2.4 million. Balance sheet cash, cash equivalents and marketable securities includes all but approximately $1.1 million in proceeds from the final closings of the $4.6 million private placement the Company and its subsidiary just concluded.

"The second quarter of 2008 was significant for ChromaDex," said Frank Jaksch (http://www.chromadex.com/AboutCDX/fjaksch.html), CEO and co-founder of ChromaDex. "We successfully completed a reverse merger acquisition of Cody Resources, Inc. a publicly quoted company on the OTCBB. We did this in order to reap the benefits of public ownership including the ability to enhance our visibility with customers and prospective customers and access to potential new avenues for capital formation. Collectively, we believe this better positions ChromaDex to help us grow and expand to meet the significant and growing needs of customers. In the second half of 2008, we will be focused on expanding our range of products and services to the market."

Additional Financial Results & Notes

On a reported basis, ChromaDex recorded revenue during the second quarter of 2008 of $1,198,885 as compared to $997,087 for the same period in 2007. The net loss attributable to common stockholders for the three months ended June 28, 2008, was $621,676 as compared to $113,926 for the same period in 2007. The Company notes that as a result of the closing of the reverse merger acquisition of Cody Resources, Inc. on June 20, 2008, investors are cautioned that the Company's historical performance is not directly comparable.

About ChromaDex

ChromaDex is a leader in the development of Phytochemical and Botanical Reference Standards and the creation of associated intellectual property. ChromaDex is committed to sustainable "Green chemistry" and provides the dietary supplement, food, beverage, nutraceutical and cosmetic industries with the analytical tools and services to meet product regulatory, quality, efficacy and safety standards.

Forward-Looking Statements

Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to ability to market, produce and sell the referenced ingredients, risks relating to product and customer demand, market acceptance of our products, the effect of economic conditions both nationally and internationally, ability to protect our intellectual property rights, impact of any litigation or infringement actions brought against us, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, the ability to complete transactions, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

ChromaDex Corporation and Subsidaries

Condensed Consolidated Statements of Operations (Unaudited)

Three Months ending

June 28, 2008 June 30, 2007

Sales $1,198,885 $997,087

Cost of goods sold 832,905 741,227

Gross profit 365,980 255,860

Operating expenses:

Selling 159,558 74,015

General and administrative 832,374 304,897

991,932 378,912

Operating loss (625,952) (123,052)

Nonoperating (income) expenses:

Interest expense 7,052 7,156

Interest income (11,550) (16,253)

Other 222 (830)

(4,276) (9,926)

Income taxes - 800

Net loss $(621,676) $(113,926)

Basic and Diluted loss per common share $(0.03) (0.01)

Basic and Diluted average common

shares outstanding 24,755,583 22,011,549

See Notes to Condensed Consolidated

Financial Statements.


'/>"/>
SOURCE ChromaDex Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ChromaDex, Inc. Announces Completion of Reverse Merger With Cody Resources, Inc.
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2016)... ... June 22, 2016 , ... Quantitative ... business incubator and current participant in the Phase 1 Ventures program, is leveraging ... , Quantitative Radiology Solutions helps physicians make better treatment decisions by quantifying ...
(Date:6/22/2016)... (PRWEB) , ... June 21, 2016 , ... New light-based ... cutting into the tissue — promise to enable both compact, wearable devices for point-of-care ... even deeper under the skin. , Recent work and visionary future directions are detailed ...
(Date:6/22/2016)... SAN DIEGO , June 22, 2016 /PRNewswire/ ... that has developed a testing platform designed specifically ... the formation of their scientific advisory board (SAB). ... of directors, the SAB is chartered to advise ... infectious disease assay platform. Led by Dr. ...
(Date:6/22/2016)... June 22, 2016 On Tuesday, June ... 4,843.76, up 0.14%; the Dow Jones Industrial Average advanced 0.14% ... 2,088.90, up 0.27%. The gains were broad based as five ... has initiated coverage on the following equities: Minerva Neurosciences Inc. ... PTLA ), Trevena Inc. (NASDAQ: TRVN ), ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
(Date:4/19/2016)... 2016 The new GEZE SecuLogic ... web-based "all-in-one" system solution for all door components. It ... the door interface with integration authorization management system, and ... The minimal dimensions of the access control and the ... installations offer considerable freedom of design with regard to ...
(Date:4/14/2016)... BioCatch ™, the global ... the appointment of Eyal Goldwerger as CEO. ... Goldwerger,s leadership appointment comes at a time of significant ... of its platform at several of the world,s largest ... unique cognitive and physiological factors, is a winner of ...
Breaking Biology News(10 mins):